Senti Bio receives FDA RMAT designation for SENTI-202

Senti Bio (SNTI)sciences announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer, CAR-NK, investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML. “This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”